ABSTRACT
Objective To investigate the β-tubulin Ⅲexpression in locally advanced cervical cancers and its significance in the neoadjuvant chemotherapy of cervical cancer .Methods Immunohistochemistry was used to detect the expression of β-tubulin Ⅲin tissue samples from 62 cases of locally advanced cervical cancer patients .Groups paclitaxel +cisplatin/carboplatin (TP) (34 pa-tients) underwent two cycles of TP chemotherapy ,while group 5-fluorouracil+cisplatin(PF) (28 patients) underwent two cycles of PF chemotherapy .Comprehensive analysis of β-tubulinⅢexpressions of TP and PF neoadjuvant chemotherapies revealed the efficien -cy and operation rate .Results The positive rate ofβ-tubulin Ⅲ was 62.90% in locally advanced cervical cancer .β-tubulin Ⅲ ex-pression was not correlated with clinicopathological features in locally advanced cervical cancer ( P >0.05 ) .β-tubulinⅢexpression was correlated with efficiency and operation rate with TP chemotherapy but not with PF chemotherapy .Conclusions In the neoadju-vant chemotherapy of locally advanced cervical cancers ,β-tubulinⅢexpression can be used as an important index to predict the effec-tive rate of combined chemotherapy containing paclitaxel and guide the patients to individual chemotherapy .
ABSTRACT
Background and purpose:Cervical cancer is one of the common disease in women in china.Radical surgery remains the first choice for patients with early-stage cervical cancer.However,the majority of patients with bulky disease have lymph nodes or metastases when diagnosed.Palatinum-based neoadjuvant chemotherapy has been utilized in locally advanced cervical cancer with the aim of improving response and survival.The study was to evaluate the effect of neoadjuvant chemotherapy followed by radical surgery for the patients with locally bulky Ⅰ_(B2) and Ⅱ_A cervical carcinoma.Methods:Between September 2003 and February 2004,51 untreated patients with Ⅰ_(B2) and Ⅱ_A cervical carcinoma were enrolled in study group,and were treated with neoadjuvant chemotherapy with cisplatin,vincristine and bleomylin for one cycle followed by radical hysterectomy and pelvic lymphadenectomy;another 51 patients as control group were treated with radical surgery alone.The tumor size,depth of stromal invasion,lymph node metastasis and involvement of surgical specimens were assessed.Results:The overall clinical response rate was 41.2%.There were no complete and progressive ones.The blood loss during operation was 116.82?45.50ml,it was significantly lower than that in control group(P